Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | PRESIDENT AND COO | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Gift · Disposed 11,728 · Balance 0 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Indirectby Trust | 99,720 |
Reported balance
After 2026-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-13 · Gift · Acquired 11,728 · Balance 99,720 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,304 | $400.39 | $922,501.09 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 19 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 8,946 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F17 · price: This transaction was executed in multiple trades at prices ranging from $400.00 to $400.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 11,250 | $102.11 | $1,148,737.50 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 18 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 2,500 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · derivative · entry 29 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 49,500 Underlying: Common Stock · 2,500 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,000 | $0.00 Strike: $102.11 | $0.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · derivative · entry 28 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 49,500 Underlying: Common Stock · 3,000 shares Expires 2026-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 4,500 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · derivative · entry 27 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $398.62 | $39,862.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 17 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 493 | $397.60 | $196,014.68 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 16 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 100 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F16 · price: This transaction was executed in multiple trades at prices ranging from $397.15 to $398.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 530 | $396.55 | $210,173.73 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 593 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F15 · price: This transaction was executed in multiple trades at prices ranging from $395.94 to $396.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $394.25 | $118,275.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,123 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F14 · price: This transaction was executed in multiple trades at prices ranging from $394.19 to $394.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $393.42 | $118,025.01 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 13 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,423 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F13 · price: This transaction was executed in multiple trades at prices ranging from $393.17 to $393.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 777 | $392.36 | $304,864.03 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,723 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F12 · price: This transaction was executed in multiple trades at prices ranging from $391.81 to $392.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 2,500 | $111.00 | $277,500.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F11 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $398.90 | $119,670.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F10 · price: This transaction was executed in multiple trades at prices ranging from $398.80 to $399.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,025 | $397.99 | $407,940.06 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 300 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F9 · price: This transaction was executed in multiple trades at prices ranging from $397.67 to $398.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 972 | $397.16 | $386,039.13 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 1,325 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F8 · price: This transaction was executed in multiple trades at prices ranging from $396.59 to $397.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,100 | $396.16 | $435,773.80 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 2,297 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $395.58 to $396.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 204 | $395.28 | $80,636.30 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 3,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $394.53 to $395.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,507 | $393.94 | $593,671.95 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 3,601 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $393.48 to $394.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,592 | $392.77 | $625,290.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 5,108 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $392.42 to $393.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 800 | $391.70 | $313,358.64 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 6,700 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $391.23 to $392.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,000 | $102.11 | $306,330.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 4,500 | $120.26 | $541,170.00 |
DisclosureSEC source: 0001415889-24-026444 · form4-11082024_041101.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 14,700 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · derivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 4,500 Underlying: Common Stock · 14,700 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $378.00 | $37,800.00 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,000 | $376.94 | $376,936.40 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 100 F8 · price: This transaction was executed in multiple trades at prices ranging from $376.5701 to $377.2793. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,803 | $375.83 | $677,622.57 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,100 F7 · price: This transaction was executed in multiple trades at prices ranging from $375.4825 to $376.3012. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,501 | $375.06 | $1,313,073.51 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,903 F6 · price: This transaction was executed in multiple trades at prices ranging from $374.47 to $375.4685. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 6,096 | $374.02 | $2,280,019.21 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 6,404 F5 · price: This transaction was executed in multiple trades at prices ranging from $373.4616 to $374.4129. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,200 | $373.05 | $447,656.88 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 12,500 F4 · price: This transaction was executed in multiple trades at prices ranging from $372.434 to $373.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 800 | $371.71 | $297,367.52 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 13,700 F3 · price: This transaction was executed in multiple trades at prices ranging from $371.41 to $372.2775. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $370.65 | $74,129.00 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 14,500 F2 · price: This transaction was executed in multiple trades at prices ranging from $370.38 to $370.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,700 | $120.26 | $1,767,822.00 |
DisclosureSEC source: 0001415889-24-025975 · form4-11042024_041101.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 14,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 20,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · derivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 19,200 Underlying: Common Stock · 20,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 5,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · derivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 52,000 Underlying: Common Stock · 5,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, in which the Reporting Person's immediate family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $326.92 | $65,383.12 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 0 F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,600 | $325.96 | $521,540.00 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 200 F11 · price: This transaction was executed in multiple trades at prices ranging from $325.72 to $326.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 600 | $324.65 | $194,787.78 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 1,800 F10 · price: This transaction was executed in multiple trades at prices ranging from $324.36 to $324.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,237 | $323.78 | $2,343,213.95 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 2,400 F9 · price: This transaction was executed in multiple trades at prices ranging from $323.33 to $324.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,300 | $322.79 | $2,356,382.33 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 9,637 F8 · price: This transaction was executed in multiple trades at prices ranging from $322.29 to $323.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,063 | $321.95 | $986,141.43 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 16,937 F7 · price: This transaction was executed in multiple trades at prices ranging from $321.19 to $322.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 20,000 | $120.26 | $2,405,200.00 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $326.01 | $163,003.80 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 0 F5 · price: This transaction was executed in multiple trades at prices ranging from $325.74 to $326.2781. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, in which the Reporting Person's immediate family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,000 | $324.18 | $324,180.50 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 500 F4 · price: This transaction was executed in multiple trades at prices ranging from $323.91 to $324.6775. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, in which the Reporting Person's immediate family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,000 | $323.24 | $646,489.40 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 1,500 F3 · price: This transaction was executed in multiple trades at prices ranging from $322.79 to $323.6906. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, in which the Reporting Person's immediate family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,500 | $322.23 | $483,350.70 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 3,500 F2 · price: This transaction was executed in multiple trades at prices ranging from $321.47 to $322.4596. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, in which the Reporting Person's immediate family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 5,000 | $111.00 | $555,000.00 |
DisclosureSEC source: 0001415889-24-020988 · form4-08082024_040802.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Reflects the exercise of options held in a trust beneficially owned by the Reporting Person, in which the Reporting Person's immediate family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| May 06, 2024 Filed May 7, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 32,200 | $0.00 Strike: $163.30 | $0.00 |
DisclosureSEC source: 0001415889-24-012466 · form4-05072024_040513.xml · derivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,200 shares Expires 2025-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 06, 2024 Filed May 7, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 32,200 | $260.51 | $8,388,422.00 |
DisclosureSEC source: 0001415889-24-012466 · form4-05072024_040513.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,577 F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| May 06, 2024 Filed May 7, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 32,200 | $163.30 | $5,258,260.00 |
DisclosureSEC source: 0001415889-24-012466 · form4-05072024_040513.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. F2 · balance_after: Includes 118, 113, and 111 shares of common stock acquired on March 4, 2022, March 3, 2023, March 4, 2024, respectively, under the United Therapeutics Corporation Employee Stock Purchase Plan. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 17,790 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001673232-26-000012 · primarydocument.xml · derivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,790 Underlying: Common Stock · 17,790 shares Expires not disclosed F5 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.